Kedokteran & Kesehatan editorial
Open AccessOA2023
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial
In the ORIENT-16 trial, adding sintilimab to chemotherapy significantly improved overall survival in patients with unresectable gastric or gastroesophageal junction cancer compared to placebo plus chemotherapy, with a median survival of 15.2 vs 12.3 months. The benefit was even more pronounced in patients with PD-L1 CPS โฅ5.
Jian-Ming Xu; Hai-Ping Jiang; Yue-Yin Pan; Kang-Sheng Gu; S. Cang; Lei Han; Yong-Qian Shu; Jia-Yi Li; Jun Zhao; H. Pan; Su-Xia Luo; Yan-Ru Qin; Qun-Yi Guo; Yu-Xian Bai; Y. Ling; Jianwei Yang; Zhilong Yan; Lei Yang; Yong Tang; Yi-Fu He; Liang-Ming Zhang; Xinjun Liang; Z. Niu; Jing-Dong Zhang; Y. Mao; Yingmei Guo; B. Peng; Zi-Ran Li; Ying Liu; Yan Wang; Hui Zhouยท Journal of the American Medical Association (JAMA)ยท 2023ยท DOI 10.1001/jama.2023.19918
The core problem
Gastric and gastroesophageal junction (GEJ) cancers are diagnosed in over 1 million people worldwide each year, and effective treatments are limited. Sintilimab, a recombinant human IgG4 monoclonal antibody targeting programmed cell death 1 (PD-1), has shown promising efficacy when combined with chemotherapy. The ORIENT-16 trial was designed to compare overall survival (OS) in patients with unresectable locally advanced or metastatic gastric/GEJ cancer treated with sintilimab plus chemotherapy versus placebo plus chemotherapy, and to evaluate a subset of patients with PD-L1 combined positive score (CPS) โฅ5.
Innovation
This randomized, double-blind, placebo-controlled, phase 3 trial was conducted at 62 hospitals in China. Between January 3, 2019, and August 5, 2020, 650 patients with unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma were enrolled. Patients were randomized 1:1 to receive either sintilimab (n=327) or placebo (n=323) combined with capecitabine and oxaliplatin (XELOX) every 3 weeks for up to 6 cycles, followed by maintenance therapy with sintilimab or placebo plus capecitabine for up to 2 years. The primary endpoint was overall survival from randomization. Final follow-up occurred on June 20, 2021.
Introduction
Gastric and gastroesophageal junction (GEJ) cancers are diagnosed in over 1 million people worldwide each year, and effective treatments are limited. Sintilimab, a recombinant human IgG4 monoclonal antibody targeting programmed cell death 1 (PD-1), has shown promising efficacy when combined with chemotherapy. The ORIENT-16 trial was designed to compare overall survival (OS) in patients with unresectable locally advanced or metastatic gastric/GEJ cancer treated with sintilimab plus chemotherapy versus placebo plus chemotherapy, and to evaluate a subset of patients with PD-L1 combined positive score (CPS) โฅ5.
Why it matters
The ORIENT-16 trial met its primary endpoint, demonstrating that the addition of sintilimab to first-line chemotherapy significantly improves overall survival in patients with advanced gastric and GEJ adenocarcinoma. The benefit was observed across the overall population and was more pronounced in patients with PD-L1 CPS โฅ5, suggesting that PD-L1 expression may serve as a predictive biomarker. The safety profile was consistent with known effects of PD-1 inhibitors and chemotherapy. These findings support sintilimab plus chemotherapy as a new first-line treatment option for this patient population. The trial was registered with ClinicalTrials.gov (NCT03745170).
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ